TRDAEntrada Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $25M
- 88% YoY
- Operating margin
- -621.1%
- 2885% YoY
- EBITDA
- −$154M
- 403% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired77% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | $129M | $211M | $25M | 88% |
| Operating income | −$51M | −$97M | −$3M | $47M | −$158M | 436% |
| Net income | −$51M | −$95M | −$7M | $66M | −$144M | 319% |
| Operating cash flow | −$51M | −$94M | $140M | −$42M | −$129M | 209% |
| Capex | $5M | $3M | $6M | $3M | $1M | 67% |
| Stock-based comp | $3M | $10M | $13M | $18M | $20M | 9.5% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $4M · 8
- Net
- −$4M
Pay vs performance
No pay-versus-performance disclosure yet.